Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.58 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.58 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.46 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336882 | 1.00 | PRKCA (0.58) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL6340272 | 0.88 | PRKCA (0.46) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL6338694 | 0.88 | ENPP2 (0.63) | LPAR1ENPP2RECQLBLMTDP1 | |
| SCHEMBL6340267 | 0.88 | PRKCA (0.46) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL8153693 | 0.88 | ENPP2 (0.63) | LPAR1ENPP2RECQLBLMTDP1 | |
| SCHEMBL6338696 | 0.88 | ENPP2 (0.63) | LPAR1ENPP2RECQLBLMTDP1 | |
| SCHEMBL16705768 | 0.85 | PRKCE (0.42) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL16520373 | 0.85 | PRKCA (0.42) | PRKCAPRKCEPRKCQPRKCDDGKA | |
| SCHEMBL23387066 | 0.83 | ALDH1A1 (0.41) | PRKCAPRKCEPRKCQPRKCDFAAH | |
| SCHEMBL16705755 | 0.83 | SOAT2 (0.45) | LPAR1FAAHCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6911553-B1 | Osteoblast-specific mitogens and drugs containing such compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | ESSWEIN ANGELIKA (DE) | 2005-01-20 | — | — | US | disclosed |
| US-6197759-B1 | ADMINISTERING LYSOPHOSPHATIDYLIC ACID DERIVATIVE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
| EP-1019062-A1 | OSTEOBLAST-SPECIFIC MITOGENS AND DRUGS CONTAINING SUCH COMPOUNDS | Roche Diagnostics GmbH (DE) | 2000-07-19 | — | — | EP | disclosed |
| WO-1999017781-A1 | OSTEOBLAST-SPECIFIC MITOGENS AND DRUGS CONTAINING SUCH COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | LPAR1, LPAR2, LPAR4 | PRKCA 592/4885PRKCE 416/4885PRKCQ 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.